FDA accepts test to be used in ARCA Biopharma trial

The FDA has accepted LabCorp's (LH) application for its diagnostic test to be used in the Phase 2B/3 "GENETIC-AF" trial of ARCA Biopharma's (ABIO) Gencaro drug for treating patients with atrial fibrillation.

Patient enrollment for the testing, in which ARCA is collaborating with Medtronic (MDT) also, is due to begin this quarter.

ARCA's shares soar 21%. (PR)

From other sites
Comments (1)
  • pat45
    , contributor
    Comments (470) | Send Message
    Wow cannot believe abio sells for little more than cash..30mil..talk about an overlooked stock. Product looks good and is in p3.
    8 Jan 2014, 10:35 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs